SAB Biotherapeutics, Inc.
NASDAQ:SABS
1.79 (USD) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 8.898 | 56.566 | 15.047 | 33.207 | 12.61 | 6.346 |
| Short Term Investments
| 11.863 | 0 | 0 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 20.761 | 56.566 | 15.047 | 33.207 | 12.61 | 6.346 |
| Net Receivables
| 0.055 | 0 | 5.557 | 8.011 | 20.569 | 2.819 |
| Inventory
| 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 2.977 | 2.341 | 1.494 | 8.975 | 1.275 | 0.124 |
| Total Current Assets
| 23.792 | 58.907 | 22.097 | 48.42 | 34.455 | 9.289 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 19.921 | 24.684 | 28.34 | 30.949 | 22.083 | 8.715 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 0.482 | 0.35 | 0.468 | 0 | 0 | 0 |
| Total Non-Current Assets
| 20.403 | 25.034 | 28.807 | 30.949 | 22.083 | 8.715 |
| Total Assets
| 44.195 | 83.941 | 50.905 | 79.369 | 56.538 | 18.004 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 1.695 | 0.946 | 3.679 | 4.459 | 7.382 | 2.171 |
| Short Term Debt
| 0.812 | 1.853 | 2.02 | 3.1 | 1.658 | 1.946 |
| Tax Payables
| 0 | 0.04 | 0.05 | 0.216 | 0 | 0 |
| Deferred Revenue
| 0 | 1.322 | 0 | 0.1 | 0.1 | 0 |
| Other Current Liabilities
| 5.473 | 6.652 | 9.244 | 16.809 | 1.922 | -4.117 |
| Total Current Liabilities
| 7.98 | 10.813 | 14.993 | 24.684 | 11.062 | 4.618 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 0 | 4.054 | 4.533 | 5.416 | 6.468 | 0.053 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 10.246 | 11.774 | 0.321 | 10.72 | 0 | 15.638 |
| Total Non-Current Liabilities
| 10.246 | 15.828 | 4.853 | 16.136 | 6.468 | 15.691 |
| Total Liabilities
| 18.226 | 26.642 | 19.847 | 40.819 | 17.53 | 20.309 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0.002 | 0.001 |
| Common Stock
| 0.001 | 0.001 | 0.005 | 0.004 | 0.004 | 0.004 |
| Retained Earnings
| -124.169 | -90.064 | -47.87 | -29.129 | -11.984 | -32.102 |
| Accumulated Other Comprehensive Income/Loss
| -0.135 | 0.026 | 0 | 0 | 0 | 0 |
| Other Total Stockholders Equity
| 150.273 | 147.336 | 78.923 | 67.675 | 50.99 | 29.792 |
| Total Shareholders Equity
| 25.97 | 57.299 | 31.058 | 38.55 | 39.008 | -2.306 |
| Total Equity
| 25.97 | 57.299 | 31.058 | 38.55 | 39.008 | -2.306 |
| Total Liabilities & Shareholders Equity
| 44.195 | 83.941 | 50.905 | 79.369 | 56.538 | 18.004 |